UCI-led Study Finds That Cancer Immunotherapy May Self-limit its Efficacy (Medicine)

Common tumor inhibitor drug triggers favorable and unfavorable immune effects

Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni, Ph.D., assistant professor of physiology & biophysics and member of the Institute for Immunology at the University of California, Irvine. Study results are published online in the journal Cell.

Using a person’s own immune system – immunotherapy – to treat cancer may also stimulate T regulatory cells, which are essential for preventing autoimmunity, in which the body attacks healthy cells and tissue, but limit tumor control. Some anticancer drugs of the checkpoint inhibitor family block the molecule CTLA-4 and activate both the CD8 and CD4 effector T cells, which kill cancer. Using intravital microscopy, a technique that allows imaging of cells within a living organism, researchers found that CTLA-4 blockage also causes the expansion of T regulatory cells, decreasing the effect of immunotherapy.

“Much of our knowledge of the mechanisms by which immunotherapy works is focused on the positive aspects of the body’s reaction, but that treatment targets the whole immune system. In this study, we investigated how Treg cells are activated within the tumor mass. We discovered that Treg cells are continuously activated in cancer. In turn, they use CTLA-4 to instruct dendritic cells to become inefficient activators of the immune system. Upon CTLA-4 inhibition, dendritic cells become more active and promote the function of effector and regulatory T cells at the same time. This has the potential of limiting efficacy and may explain the failure of immunotherapy in some patients,” said Marangoni, corresponding author on the study.

Future research will focus on identifying and removing unwanted immune reactions in other forms of immunotherapy. In particular, new strategies must be developed to decrease the activation of Treg cells in a controlled manner in order to avoid “fatal autoimmunity,” Marangoni said: “The indiscriminate depletion of Treg cells would cause the CD8 and CD4 effector T cells to attack our body and potentially kill us.”

The research team also included physicians and scholars from Harvard Medical School and Massachusetts General Hospital in Boston, The University of Texas MD Anderson Cancer Center in Houston, and Germany’s University of Cologne and University of Lübeck. This work was supported by several National Institutes of Health grants, a Melanoma Research Foundation award and a Sara Elizabeth O’Brien/Charles A. King Trust fellowship.

Featured image: T regulatory cells (green with red nuclei) interact with antigen-presenting cells (magenta) in a tumor (blue). The Treg cell on top is activated (green fluorescence in the nucleus), while the one at the bottom is not (green fluorescence outside the nucleus). Activation of Treg cells promotes tumor growth. Courtesy of Francesco Marangoni


Provided by University of California, Irvine

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s